Having trouble accessing articles? Reset your cache.

Tarceva OPTIMAL in first-line NSCLC

Roche (SIX:ROG; OTCQX:RHHBY) said once-daily oral Tarceva erlotinib met the primary endpoint of significantly improving progression-free survival

Read the full 175 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE